(Q37045295)

English

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

scientific article published on 28 June 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

0 references

author name string

Christian Lehmann

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Thomas Friess

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Fabian Birzele

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Anna Kiialainen

4

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Markus Dangl

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

publication date

28 June 2016

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Journal of Hematology & Oncology

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

50

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

describes a project that uses

object named as

DESeq

1 reference

CZ Software Mentions: A large dataset of software mentions in the biomedical literature

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Advances in treating acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Strategies for modern biomarker and drug development in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Fast gapped-read alignment with Bowtie 2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Differential expression analysis for sequence count data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Mapping and quantifying mammalian transcriptomes by RNA-Seq

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

p53 in hematologic malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

29 September 2017

Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

27 June 2018

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

27 June 2018

Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

4 September 2018

High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4924270

4 September 2018

The human MDM-2 oncogene is overexpressed in leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/27353420

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of the p53 and MDM-2 gene in acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/27353420

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/27353420

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S13045-016-0280-3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37045295&oldid=2199791498"